Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali

• Status: Not yet recruiting
• Trial end date: 2021-12-01

Summary

The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artemether-lumefantrine (AL) with and without a single dose of 0.25mg/kg primaquine (PQ) and sulfadoxine-pyrimethamine with amodiaquine (SPAQ) with and without single dose of 1.66mg/kg tafenoquine (TQ). Outcome measures will include infectivity to mosquitoes at 2, 5 and 7 days after treatment, gametocyte density throughout follow-up, and safety measures including haemoglobin density and the frequency of adverse events.

• Phase: Phase 2

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Treatments: Amodiaquine; Artemether; Artemether, Lumefantrine Drug Combination; Fanasil, pyrimethamine drug combination; Lumefantrine; Primaquine; Pyrimethamine; Sulfadoxine; Tafenoquine